OSE Immuno - Ph2 for ulcerative colitis well on track
*OSE Immuno announced completion of enrolment in its Ph2 for ulcerative colitis (UC): readout timing (mid-2024) reiterated. *Following a (successful) readout in this Ph2 in UC, we expect OSE to search for a pharma partner to conduct the Ph3 and subsequent commercialization but do not envision this to be a walk in the park, mainly due to the highly competitive nature of the UC market. *No impact on estimates and investment case.Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.